MarginsXMarginsX
Home › Markets › Health Care › SILO

Silo Pharma Inc. (SILO)

SILO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.57
-14.40% on the day
Market cap
$3.4M
Nano cap
Revenue · 2025
$72K
0.0% on 2024
Net income · 2025
-$4.2M
-5863.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/0001213900-26-035576-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSILO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001514183
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$72K
Net income-$4.2M
Operating income-$4.3M
Net margin-5863.5%
Operating margin-5937.0%
Revenue growth0.0%
Cash$4.7M
Total assets$7.6M
P/E (computed)Net income was not positive
P/S (computed)47.1×

Warning signs

Cash runway
11.8 months
$3.3M cash at June 30, 2026
Share count, 1 year
+142.9%
2025-11-13 to 2026-11-13 · +940.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$8K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The positive working capital and the July 2026 Private Placement (see Note 6) and November 2026 Private Placement (see Note 8) serve to mitigate the conditions that historically raised substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$3.3M cash; operating cash flow -$835K a quarter.Report 2026-06-30
Shares outstanding2,156,292 (2026-11-13); 13,318,273 a year earlier; 3,108,797 three years earlier. 1y figure adjusted for splits (1-for-15 overall); 3y figure adjusted for splits (1-for-15 overall).Cover page 2026-11-13
Reverse splits, 3 years1; latest 1-for-15 on 2026-06-03Source 2026-06-03
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-24
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-12-29
AuditorSalberg & Company, P.A., Boca Raton, Florida, United StatesPCAOB Form AP 2026-04-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $8K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$833K-$782K$3.3MNo debt tags$54K10-Q 2026-08-13
Q1 2026
2026-03-31
$18K-$1.6M-$823K$3.9MNo debt tags$72K10-Q 2026-05-14
Q4 2025
2025-12-31
$18K-$882K-$780K$4.7MNo debt tags$72K10-K 2026-03-27
Q3 2025
2025-09-30
$18K-$1.1M-$955K$3.9MNo debt tags$72K10-Q 2025-11-13
Q2 2025
2025-06-30
$18K-$1.2M-$1.3M$4.3MNo debt tags$72K10-Q 2026-08-13
Q1 2025
2025-03-31
$18K-$1.0M-$1.6M$3.1MNo debt tags$72K10-Q 2026-05-14
Q4 2024
2024-12-31
$18K-$1.7M-$917K$3.9MNo debt tags$72K10-K 2026-03-27
Q3 2024
2024-09-30
$18K-$929K-$1.3M$4.9MNo debt tags$72K10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-08-06
Latest annual report
ANNUAL REPORT
10-K2026-03-27
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-13
Latest current report
CURRENT REPORT
8-K2026-11-06
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-06-30

Source: SEC EDGAR submissions feed, 382 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+38.3%
1 month+50.8%
3 months-42.9%
Year to date-63.9%
1 year-71.8%
From 52-week high-81.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XBIOXenetic Biosciences Inc.$1.49-10.24%$3.5M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
XTLBXTL Biopharmaceuticals Ltd.$1.54-3.75%$3.8M
AZTRAzitra Inc$0.6270+3.06%$3.8M
GELSGelteq Limited$0.3589-5.63%$3.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier